Oligodendroglioma
Section snippets
Incidence, age at presentation
Oligodendroglioma (OD) constitutes 5–20% of all glial tumors and about 1500 new cases are diagnosed in Europe each year. OD is a rare tumor with an annual incidence rate of 0.2 per 100,000 people in Europe [1]. They are predominantly a tumor of adulthood, with a peak incidence between the fourth and sixth decade of life. About 55% of all cases are between 40 and 64 years of age. In Europe, the annual incidence is 0.4 per 100,000 for this age group [1]. Low-grade OD tends to arise in slightly
Histology
Most OD arises in the white matter of cerebral hemispheres, predominantly in the frontal lobes. They can arise, however, throughout the CNS, including infratentorial sites and the spinal cord. They diffusely infiltrate brain tissue but, in contrast to astrocytoma, areas of remarkable sharp borders with surrounding brain tissue can often be found. The current WHO definition of oligodendroglioma is “a well-differentiated, diffusely infiltrating tumor of adults, typically located in the cerebral
Diagnosis
The clinical signs and symptoms of OD are unspecific, and depend on the localization and progression of the tumor. They may present with seizures, cognitive deficits, or focal deficits. Low-grade OD tend to present with seizures, whereas patients with high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits early in the course of the disease. On magnetic resonance imaging (MRI), low-grade ODs show increased signal intensity on T2-weighted images
Staging
Similarly to other astrocytomas, OD tend to remain localized to the CNS. Extra-CNS metastasis (especially bone metastasis) has been described but this is very rare and occurs in the occasional patient only at later stages of the disease. Leptomeningeal spread is less rare, but again usually does not develop until the time of recurrence. Therefore, there is no need for routine specific staging procedures (like craniospinal axis imaging or CSF sampling). In patients with recurrent disease the
Histology
Pure oligodendroglial tumors have a better prognosis than astrocytic tumors of the same grade; the prognosis of mixed oligoastrocytoma appears to be in between these histologies. Most likely, this is the result of underlying genetics (absence or presence of 1p/19q co-deletion; see below). Despite the relatively favorable clinical prognosis of OD, the outcome is ultimately fatal for virtually all patients.
Tumor grade
Prior to the era of genetics, tumor grade was the single most important prognostic factor
Long-term sequelae
Cognitive and focal neurological deficits may have a great impact on long-term survivors of brain tumors, regardless of the histology and grade of the tumors. Memory loss, apathy, concentration difficulties and personality changes may have a profound effect even in those patients who appear to have a Karnofsky performance status of 100. Surgery in so-called silent areas may contribute to cognitive deficits. Less clear are the late effects of radiation therapy on cognitive function. Radiotherapy
Follow-up
No general guidelines for the follow-up of OD can be given, these should be tailored to the individual patient taking tumor grade, genotype, previous treatments and remaining treatment options into account. Low-grade glioma patients should be followed, even if the lesion is stable for many years. At some point in time, progression will occur and treatment should be installed before irreversible deficits occur. To avoid significant undetected progression, it is recommended to make follow-up
Conclusions
Oligodendroglioma, in particular with 1p/19q loss have a more indolent clinical behaviour, are more sensitive to treatment and have a better overall prognosis compared to astrocytoma or non-1p/19q deleted oligodendroglial tumors of similar grade. This implies that more treatment options are available, but also that delayed side effects of treatment are a potential issue. Because of the better outcome and the relative rarity of the disease studies into this tumor type are very difficult and
Reviewers
Dr. Roger Stupp, Multidisciplinary Oncology Center, CHUV, Vaud University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland
Prof. Pierre-Yves Dietrich, Department of Oncology, University Hospital of Geneva, Rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
Acknowledgments
The authors thank the members of the EUROCARE Working Group for permitting the survival analysis from the EUROCARE dataset.
Martin J van den Bent is head of the neuro-oncology unit of the Daniel den Hoed Cancer Center in Rotterdam, the Netherlands, and chair of the European Organisation of Research and Treartment of Cancer (EORTC) Brain Tumor Group. He has conducted several clinical trials on oligodendroglial tumors.
References (77)
- et al.
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
Am J Pathol
(1999) - et al.
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study
Lancet
(2002) - et al.
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
Lancet
(2005) - et al.
A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844
Int J Radiat Oncol Biol Phys
(1996) - et al.
The role of postoperative irradiation in the treatment of oligodendroglioma
Int J Radiat Oncol Biol Phys
(1994) - et al.
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Eur J Cancer
(2006) - et al.
Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters
Radiother Oncol
(1996) - ENCR. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.2 (1999), Lyon;...
- et al.
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group
J Clin Oncol
(1994) - et al.
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group
Neurology
(1998)
Survival of cancer patients in Europe: the EUROCARE-3 study
Ann Oncol
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
Cancer
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
J Natl Cancer Inst
Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
Oncogene
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
Cancer
Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss
J Neuropathol Exp Neurol
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Cancer Res
Molecular pathology and clinical characteristics of oligodendroglial neoplasms
Ann Neurol
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
N Engl J Med
Oligodendroglioma
Oligoastrocytomas: a clinicopathological study of 52 cases
J Neurooncol
Molecular genetic evidence for subtypes of oligoastrocytomas
J Neuropathol Exp Neurol
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
Am J Pathol
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
J Clin Oncol
Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization
J Neuropathol Exp Neurol
Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”
J Neuropathol Exp Neurol
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression
Neurology
Intracranial oligodendrogliomas: imaging findings in 35 untreated cases
AJR Am J Roentgenol
Imaging correlates of molecular signatures in oligodendrogliomas
Clin Cancer Res
Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation
J Clin Oncol
Oligodendrogliomas: the Mayo Clinic experience
J Neurosurg
Supratentorial gliomas: a comparative study by grade and histologic type
J Neurooncol
Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma
J Neurosurg
Oligodendroglioma. A comparison of two grading systems
Cancer
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
J Clin Oncol
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial
J Clin Oncol
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis
Clin Cancer Res
Cited by (67)
Diagnostic Pathology: Pediatric Neoplasms
2018, Diagnostic Pathology: Pediatric NeoplasmsTumors of the central nervous system
2018, Nanotechnology-Based Targeted Drug Delivery Systems for Brain TumorsTERT promoter mutations contribute to subset prognostication of lower-grade gliomas
2015, Modern Pathology
Martin J van den Bent is head of the neuro-oncology unit of the Daniel den Hoed Cancer Center in Rotterdam, the Netherlands, and chair of the European Organisation of Research and Treartment of Cancer (EORTC) Brain Tumor Group. He has conducted several clinical trials on oligodendroglial tumors.
Michele Reni is coordinator of the clinical research and vice director of the Medical Oncology Unit, San Raffaele Scientific Institute, Milan, Italy.
Gemma Gatta is Assistant Researcher in the Unit of Epidemiology of Istituto Nazionale Tumori, Milan, Italy. She is involved in projects with population-based cancer registries on incidence, survival and prevalence.
Charles J. Vecht (1947) is a neurologist–oncologist at the Medical Centre The Hague in The Netherlands, where he is the coordinator of the Hospital Neuro-oncology Program. Dr. Vecht's clinical research focuses mainly on primary brain tumors with a special interest for epilepsy associated with cancer.